Welcome to our dedicated page for MiNK Therapeutics news (Ticker: INKT), a resource for investors and traders seeking the latest updates and insights on MiNK Therapeutics stock.
MiNK Therapeutics, Inc. (NASDAQ: INKT) is a clinical-stage biopharmaceutical company dedicated to developing cutting-edge therapies for treating cancer and other immune-mediated diseases. The company's core focus lies in pioneering allogeneic invariant natural killer T (iNKT) cell therapies, which are designed to be off-the-shelf solutions, making them readily available for patients in need.
MiNK's flagship program, agenT-797, is currently in a Phase 2 trial aimed at treating second-line gastroesophageal cancer. This trial, led by Dr. Yelena Janjigian at Memorial Sloan Kettering Cancer Center, builds on promising results from earlier studies where agenT-797 demonstrated the ability to overcome resistance to immune checkpoint inhibitors. The trial is exploring the combination of agenT-797 with other advanced treatments, such as botensilimab and balstilimab, to improve outcomes for patients with challenging gastrointestinal cancers.
Another significant candidate in MiNK's pipeline is MiNK-215, an IL-15 armored FAP-targeting CAR iNKT cell therapy. This candidate has shown remarkable efficacy in preclinical models for colorectal cancer liver metastases, overcoming the immune barriers typically posed by liver metastases.
The company recently reported a strong year-end financial position with ongoing collaborations, including a research agreement with ImmunoScape. MiNK Therapeutics continues to advance its clinical programs while maintaining a focus on scalable and reproducible manufacturing processes for its iNKT cell therapies.
Founded and headquartered in New York, NY, MiNK Therapeutics remains committed to delivering innovative and effective treatments for life-threatening diseases. For more information, visit their website or follow them on social media at @MiNK_iNKT.
MiNK Therapeutics, a clinical-stage biopharmaceutical company, announced that Dr. Jennifer Buell, President and CEO, will participate in a fireside chat at the HC Wainwright Cell Therapy Virtual Conference on February 28 at 9:00 AM ET. The chat will focus on MiNK's pioneering work in allogeneic invariant natural killer T (iNKT) cell therapies aimed at treating cancer and immune-mediated diseases. Interested participants can access the live chat here, with a replay available on MiNK's website thereafter.
MiNK Therapeutics, a clinical-stage biopharmaceutical company, announced that Dr. Jennifer Buell, President and CEO, will participate in a fireside chat at the 3rd Annual B. Riley Securities Oncology Conference on January 18th, at 11:00 AM ET. The live chat can be accessed via B. Riley's website, with a replay available afterward on MiNK's Events and Presentations page. The conference, taking place on January 18-19, will showcase over 30 healthcare companies focusing on innovations in cancer treatment, featuring discussions by key opinion leaders in the field.
MiNK Therapeutics, a biopharmaceutical company, announced that Dr. Jennifer Buell, President and CEO, will participate in a fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on December 1st at 4:45 PM ET. The event will be accessible live via a provided link, with a replay available on the MiNK website afterward. Recently, MiNK presented new data from five presentations at the Society for Immunotherapy of Cancer Annual Meeting on November 10th, showcasing their innovative iNKT cell therapies aimed at treating cancer and immune-mediated diseases.
MiNK Therapeutics announced promising results for its allogeneic iNKT cell therapy, agenT-797, showcasing early clinical activity in solid tumors with 27% of patients achieving disease stabilization alone and 66% in combination with pembrolizumab or nivolumab. Noteworthy is the survival benefit observed in viral ARDS patients, with a 70% survival rate versus 10% in controls. Moreover, agenT-797 demonstrated a favorable safety profile with no cytokine release syndrome reported, and the company is advancing new candidates for next-generation CAR-iNKT therapies.
MiNK Therapeutics reported third-quarter 2022 financial results, highlighting a net loss of $6.3 million ($0.19 per share), a significant reduction from a net loss of $14.3 million ($0.59 per share) in Q3 2021. The company had a cash balance of $24.2 million as of September 30, 2022, down from $38.9 million at the end of 2021. Operational cash usage increased, reflecting the internalization of cGMP manufacturing for clinical trials. The firm will present at the Society of Cancer Immunotherapy Meeting, showcasing clinical data on its iNKT cell therapies.
MiNK Therapeutics will release its third quarter 2022 financial results on November 3rd, 2022, before the market opens. A conference call is scheduled for 8:30 a.m. ET the same day, providing insights into the company's progress in developing allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases.
The company focuses on scalable and reproducible manufacturing methods for its therapies, aiming for off-the-shelf delivery to patients.
MiNK Therapeutics is set to host a Research & Development Day on November 10, 2022, from 4:00 to 6:00 PM ET in Boston, MA, and via webcast. The event will highlight the company’s novel allogeneic iNKT cell therapy platform and feature insights from clinical trials and next-gen programs. Presentations will cover initial data from a phase 1 trial of iNKTs with anti-PD-1 inhibitors, as well as advancements in the FAP-CAR-iNKT program. The event will include leading immuno-oncology experts and is open to institutional investors.
MiNK Therapeutics announced the acceptance of five abstracts at the Society for Immunotherapy of Cancer’s 37th Annual Meeting, scheduled for November 8-12, 2022. These abstracts focus on clinical data for AgenT-797, a novel allogeneic invariant natural killer T (iNKT) cell therapy targeting advanced solid tumors, viral ARDS, and refractory multiple myeloma. New therapeutic candidates, MiNK-215 and MiNK-413, are also highlighted, showcasing advancements in CAR-iNKT therapy. The meeting will feature presentations from several experts, emphasizing the company's commitment to innovative cancer treatments.
MiNK Therapeutics, a biopharmaceutical firm focused on allogeneic iNKT cell therapies for cancer and immune diseases, will participate in two investor conferences this September. The HC Wainwright 24th Annual Global Investment Conference will feature a webcast on September 12th at 7:00 AM ET. Additionally, MiNK will participate in the Baird 2022 Global Healthcare Conference on September 14th at 1:25 PM ET. Both events will allow investors to explore MiNK's innovative therapies. Webcast replays will be available on the Company’s website.
MiNK Therapeutics reported its Q2 2022 financial results, highlighting ongoing advancements in its clinical programs, particularly AgenT-797 for cancer and viral ARDS. The company completed internal cGMP production capable of treating over 700,000 patients annually. Clinical data updates for AgenT-797 and a novel stromal-CAR-iNKT program are anticipated in the second half of 2022. Financially, MiNK ended Q2 with $29.8 million in cash and reported a net loss of $6.1 million, slightly improving from the previous year. The leadership team has also been expanded, notably appointing Dr. Joy Zhou as VP of CMC.
FAQ
What is the current stock price of MiNK Therapeutics (INKT)?
What is the market cap of MiNK Therapeutics (INKT)?
What does MiNK Therapeutics specialize in?
What is agenT-797?
What are the recent achievements of MiNK Therapeutics?
Where is MiNK Therapeutics headquartered?
What partnerships has MiNK Therapeutics established?
What is MiNK-215?
How does MiNK Therapeutics deliver their therapies?
How can investors get more information about MiNK Therapeutics?
What is the primary focus of MiNK Therapeutics' current research?
How does agenT-797 work?
